STOCK TITAN
  1. Home
  2. News
  3. MLTX

MoonLake Immunotherapeutics - MLTX STOCK NEWS

Welcome to our dedicated news page for MoonLake Immunotherapeutics (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MoonLake Immunotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MoonLake Immunotherapeutics's position in the market.

News
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 
Rhea-AI Summary
MoonLake Immunotherapeutics partners with Komodo Health to enhance research on inflammatory skin and joint conditions, aiming to improve treatment for patients with hidradenitis suppurativa and active psoriatic arthritis. The collaboration will leverage Komodo's data and technology to accelerate the development of MoonLake's nanobody-based therapy, with a focus on market research, clinical trial site selection, and patient journey mapping.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
partnership
-
News
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
Rhea-AI Summary
MoonLake Immunotherapeutics announces positive 24-week data from the ARGO trial of sonelokimab in psoriatic arthritis, showcasing significant improvements and multi-domain responses. The Company also plans to commence Phase 3 trials in hidradenitis suppurativa, targeting a market opportunity exceeding $10bn by 2035. MoonLake further announces the initiation of four additional clinical trials across dermatology and rheumatology, highlighting the potential of sonelokimab in various inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
Rhea-AI Summary
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024. MoonLake, a biotechnology company, will showcase 24-week data from its Phase 2 MIRA trial at the AAD Annual Meeting, highlighting the therapeutic effect of sonelokimab in treating moderate to severe hidradenitis suppurativa.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
conferences
News
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
Rhea-AI Summary
MoonLake Immunotherapeutics reports positive financial results for 2023, highlights successful Phase 2 trials for sonelokimab, and plans R&D Day. Cash reserves of $511.0 million, R&D Day scheduled for March 10 alongside AAD meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.09%
Tags
earnings
-
News
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Rhea-AI Summary
MoonLake Immunotherapeutics receives positive feedback from FDA and EMA for Phase 3 program of Nanobody sonelokimab in Hidradenitis Suppurativa, with clear regulatory path outlined. Phase 3 trial to enroll 800 patients, primary endpoint readout expected in mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
clinical trial
-
News
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
MoonLake Immunotherapeutics (NASDAQ: MLTX) reports Q3 2023 financial results, positive clinical data from global Phase 2 MIRA and ARGO trials for sonelokimab, ending Q3 with $496.0 million in cash. The Nanobody® sonelokimab shows promise in treating hidradenitis suppurativa and psoriatic arthritis. MoonLake is in discussions with regulatory authorities for Phase 3 planning in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
earnings
News
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Rhea-AI Summary
MoonLake Immunotherapeutics announces positive Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis. Primary endpoint ACR50 met with up to 47% of patients achieving ACR50 at week 12. Other secondary endpoints also reached statistical significance. Discontinuation rate below 4% and safety results consistent with previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
Rhea-AI Summary
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
clinical trial
-
News
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
Rhea-AI Summary
MoonLake announces that Phase 2 MIRA trial results for Nanobody sonelokimab in hidradenitis suppurativa will be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress. The trial achieved positive topline results, making it the first placebo-controlled randomized trial in HS to report positive top-line results. The 24-week Phase 2 MIRA trial data is anticipated soon. Top-line results for MoonLake's Phase 2 ARGO trial in psoriatic arthritis are expected in November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
News
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
Rhea-AI Summary
MoonLake Immunotherapeutics to host Capital Markets Day on Sep 11. Will discuss psoriatic arthritis market and upcoming trial results. Positive top-line results from Phase 2 MIRA trial in June. External speaker presentation. Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
Stock MLTX logo
MoonLake Immunotherapeutics

Nasdaq:MLTX

MLTX Rankings

#1659 Ranked by Market Cap
#10 Ranked by Stock Gains
N/A Ranked by Dividends

MLTX Stock Data

2.76B
23.47M
9.42%
96.64%
12.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Switzerland
Zug

About MLTX

moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.